
<!DOCTYPE html>
<!--[if lt IE 8]>      <html class="no-js nav theme-teal lt-ie10 lt-ie9 lt-ie8  " lang="en-us"> <![endif]-->
<!--[if IE 8]>         <html class="no-js nav theme-teal lt-ie10 lt-ie9  " lang="en-us"> <![endif]-->
<!--[if IE 9]>         <html class="no-js nav theme-teal lt-ie10  " lang="en-us"> <![endif]-->
<!--[if !IE]><!-->     <html class="no-js nav theme-teal  " lang="en-us" > <!--<![endif]-->	
    <head>
        <meta charset="utf-8" />
                		<title>Surveillance Manual | Hepatitis B | Vaccine Preventable Diseases | CDC</title>
        		
        <meta name="description" content="Vaccines: Hepatitis B - Manual for The Surveillance of Vaccine-Preventable Diseases (Chapter 4)" />        <meta name="keywords" content="manual, surveillance manual, surveillance of VPD, vaccine preventable disease surveillance, disease surveillance, hepb, hep b, hepatitis b, hep b surveillance, hepatitis surveillance, surveillance of hepatitis, hepatitis disease" />		<meta name="viewport" content="width=device-width, initial-scale=1" />
		        <link rel="apple-touch-icon-precomposed" sizes="144x144" href="../../../TemplatePackage/3.0/images/cdc-touch-icon-144x144.png" />
        <link rel="apple-touch-icon-precomposed" sizes="114x114" href="../../../TemplatePackage/3.0/images/cdc-touch-icon-114x114.png" />
        <link rel="apple-touch-icon-precomposed" sizes="72x72" href="../../../TemplatePackage/3.0/images/cdc-touch-icon-72x72.png" />
        <link rel="apple-touch-icon-precomposed" href="../../../TemplatePackage/3.0/images/cdc-touch-icon-57x57.png" />
        <link rel="shortcut icon" href="../../../TemplatePackage/3.0/images/favicon.ico" />	
		
		<meta name="robots" content="index,follow" />
		<meta property="cdc:template_version" content="3.0" />
		<meta property="cdc:content-id" content="809937"/>
		<meta property="cdc:revision-id" content="2"/>
				<link rel="canonical" href="http://www.cdc.gov/vaccines/pubs/surv-manual/chpt04-hepb.html"/>
				<!-- Internal Release Version # 3.7 -->
                			<link rel="stylesheet" href="../../../TemplatePackage/3.0/css/lib/bootstrap24.css" />
	<link rel="stylesheet" href="../../../TemplatePackage/3.0/css/app.css@3.2.1.7.css" />
	<!--[if gt IE 9]><!--><!--<![endif]-->
	<!--[if IE 7]>
		<link rel="stylesheet" href="/TemplatePackage/3.0/css/lib/font-awesome-ie7.css" />
	<![endif]-->
	<!--[if lt IE 9]>
		<link rel="stylesheet" href="/TemplatePackage/3.0/css/ie.css" />
	<![endif]-->
	<link rel="stylesheet" media="print" href="../../../TemplatePackage/3.0/css/print.css@3.2.1.7.css" />
	<script src="../../../TemplatePackage/3.0/js/libs/modernizr-latest.js"></script>
	<script>
		if(!Date.now){Date.now=function now(){return new Date().getTime()}}
		var page_timing = page_timing || {};
		page_timing.page_start = Date.now();
		function $$(e){if(window.$){e()}else{setTimeout(function(){$$(e)},50)}}
		// (function(){function e(e,t){var n=e.length;while(n--){if(e[n].indexOf(t)>-1){return e[n]}}return false}var t=e(document.getElementsByTagName("html")[0].className.split(" "),"theme-");if(t){var n=document.createElement("link");n.rel="stylesheet";n.type="text/css";n.media="screen";n.href="/TemplatePackage/3.0/css/themes/"+t+".css";document.getElementsByTagName("head")[0].appendChild(n)}})();

		var settings = {}, addthis = null;
	</script>

	<meta name="application-name" content="CDC.gov"/>
	<meta property="cdc:template_version" content="3.2.1.7" />
	<meta name="msapplication-TileColor" content="#0061aa" />
	<meta name="msapplication-square70x70logo" content="/TemplatePackage/3.0/images/Win8_tile_70x70.png" />
	<meta name="msapplication-square150x150logo" content="/TemplatePackage/3.0/images/Win8_tile_150x150.png" />
	<meta name="msapplication-wide310x150logo" content="/TemplatePackage/3.0/images/Win8_tile_310x150.png" />
	<meta name="msapplication-square310x310logo" content="/TemplatePackage/3.0/images/Win8_tile_310x310.png" />
	<meta name="viewport" content="width=device-width,initial-scale=1,shrink-to-fit=no">		        <link rel="stylesheet" href="../../../TemplatePackage/3.0/css/timeline.css" />

        


      <style type="text/css">@import "../../~inc~/local.css";</style>
  


        <!-- OLD TITLE BEFORE 4/7/2016 <title>CDC - Surveillance of Hepatitis B - Chapter 4 - Vaccine Preventable Diseases</title> -->
<!-- OLD TITLE BEFORE "070711" <title>Vaccines: Pubs/SurvManual/Hepatitis B Chapter 4</title> -->
<!-- OLD URL BEFORE "070711" http://www.cdc.gov/vaccines/pubs/surv-manual/chpt04-hepb.htm -->
<!-- OLD CHANNEL NAME remained same at "070711" Vaccines -->
<!-- channel="Vaccines" same channel as of "070711" -->
<!-- Level 1="NCIRD" new level 1 as of "070711" -->
<!-- Level 2="Surveillance" new level 2 as of "070711" -->
        		    </head>
    <body>
				



				<div id="skipmenu">
	<a href="chpt04-hepb.html#searchTarget" class="skippy">Skip directly to search</a>
	<a href="chpt04-hepb.html#azTab" class="skippy">Skip directly to A to Z list</a>
	<a href="chpt04-hepb.html#nav-container" class="skippy">Skip directly to navigation</a>
	<a href="chpt04-hepb.html#share-bar" class="skippy">Skip directly to page options</a>
	<a href="chpt04-hepb.html#contentArea" class="skippy">Skip directly to site content</a>
</div>		    	<div id="wrapper">
    		
<!-- references to this removed intentionally -->
    		<header id="header">
    			<div class="container">
                    <div class="row">
                    	<div id="logo" class="span14">
                    		<!--iPad touch response and 508 voice reader issue currently under investigation -->
<a href="../../../index.html" title="Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People">
	<img src="../../../TemplatePackage/3.0/images/masthead_subpage.svg" alt="Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People" class="hidden-one" />
	<img src="../../../TemplatePackage/3.0/images/masthead_1-col.svg" alt="Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People" class="visible-one" />
</a>

<!-- IOS9 iPad bug work around - make sure screen readers have a readable version of the logo to read
<a class="tp-sr-only" href="https://www.cdc.gov">Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People</a>
 -->
                    	</div>
                    	<!-- search -->
                    	<div id="searchArea" class="span10 hidden-one hidden-two">							
							
<div class="hidden"><a href="chpt04-hepb.html#" name="searchTarget">Start of Search Controls</a></div>
<form class="searchForm" method="get" action="https://search.cdc.gov/search">
	<fieldset class="search-form-wrapper ">
		<legend>Search Form Controls</legend>
		<div class="search-form-checkbox">
			<label class="subset"><input type="checkbox" name="subset" checked="checked" value="">Search The CDC</label>
		</div>
		<div class="search-input-wrapper">
			<div class="search-buttons">
				<button class="btn-clear"><span class="sprite-14-close">Cancel</span></button>
				<button class="btn-submit"><span class="sprite-14-search-black">Submit</span></button>
				<input type="submit" value="Submit" style="display:none; visibility:hidden;" /> 
			</div>
			<div class="search-input">
				<label><input type="text" placeholder="SEARCH" name="query" /><span class="hidden">Search The CDC</span></label>
			</div>
		</div>
		<input type="hidden" name="utf8" value="&#x2713;" />
					<input type="hidden" name="affiliate" value="cdc-main" />
			</fieldset>
</form>							<div class="a2z-button pull-right hidden-one hidden-two"><a href="chpt04-hepb.html#" id="azTab">CDC A-Z Index <span class="icon-angle-down"></span></a></div>
                    	</div>
                    </div>
                    	<div class="hidden-three hidden-four" id="mobile-menu">
		<ul>
			<li id="vp1-menu-button" class="border-bottom-white"><a href="chpt04-hepb.html#" id="menu-nav"><span class="sprite-16-menu"></span>MENU</a></li>
			<li id="vp1-a2z-button" class="border-bottom-white"><a href="chpt04-hepb.html#" id="menu-az">CDC A-Z</a></li>
			<li id="vp1-search-button" class="border-bottom-white"><a href="chpt04-hepb.html#" id="menu-search"><span class="sprite-16-search-white"></span>SEARCH</a></li>
		</ul>
	</div>
<script>if (typeof page_timing !== 'undefined') { page_timing.menu_load = Date.now(); }</script>
                    <div class="a2z-bar hide">
                    	<div>
	<ul>
		<li><a href="../../../az/a.html">A</a></li>
		<li><a href="../../../az/b.html">B</a></li>
		<li><a href="../../../az/c.html">C</a></li>
		<li><a href="../../../az/d.html">D</a></li>
		<li><a href="../../../az/e.html">E</a></li>
		<li><a href="../../../az/f.html">F</a></li>
		<li><a href="../../../az/g.html">G</a></li>
		<li><a href="../../../az/h.html">H</a></li>
		<li><a href="../../../az/i.html">I</a></li>
		<li><a href="../../../az/j.html">J</a></li>
		<li><a href="../../../az/k.html">K</a></li>
		<li><a href="../../../az/l.html">L</a></li>
		<li><a href="../../../az/m.html">M</a></li>
		<li><a href="../../../az/n.html">N</a></li>
		<li><a href="../../../az/o.html">O</a></li>
		<li><a href="../../../az/p.html">P</a></li>
		<li><a href="../../../az/q.html">Q</a></li>
		<li><a href="../../../az/r.html">R</a></li>
		<li><a href="../../../az/s.html">S</a></li>
		<li><a href="../../../az/t.html">T</a></li>
		<li><a href="../../../az/u.html">U</a></li>
		<li><a href="../../../az/v.html">V</a></li>
		<li><a href="../../../az/w.html">W</a></li>
		<li><a href="../../../az/x.html">X</a></li>
		<li><a href="../../../az/y.html">Y</a></li>
		<li><a href="../../../az/z.html">Z</a></li>
		<li><a href="../../../az/0.html">#</a></li>
	</ul>
</div>
<script>if (typeof page_timing !== 'undefined') { page_timing.a2z_load = Date.now(); }</script>                    </div>
                    <div id="searchArea-two-column" class="span24 searchbar hide hidden-three hidden-four">
						  
<div class="hidden"><a href="chpt04-hepb.html#" name="searchTarget">Start of Search Controls</a></div>
<form class="searchForm" method="get" action="https://search.cdc.gov/search">
	<fieldset class="search-form-wrapper ">
		<legend>Search Form Controls</legend>
		<div class="search-form-checkbox">
			<label class="subset"><input type="checkbox" name="subset" checked="checked" value="">Search The CDC</label>
		</div>
		<div class="search-input-wrapper">
			<div class="search-buttons">
				<button class="btn-clear"><span class="sprite-14-close">Cancel</span></button>
				<button class="btn-submit"><span class="sprite-14-search-black">Submit</span></button>
				<input type="submit" value="Submit" style="display:none; visibility:hidden;" /> 
			</div>
			<div class="search-input">
				<label><input type="text" placeholder="SEARCH" name="query" /><span class="hidden">Search The CDC</span></label>
			</div>
		</div>
		<input type="hidden" name="utf8" value="&#x2713;" />
					<input type="hidden" name="affiliate" value="cdc-main" />
			</fieldset>
</form>					</div>
                    <!--
	See the noscript include for modifying the emergency message. DO NOT add it here.
-->
<script>if (typeof page_timing !== 'undefined') { page_timing.emergency_load = Date.now(); }</script>
    				<div class="titlebar">
					 						<h2>


<a href="index.html">Manual for the Surveillance of Vaccine-Preventable Diseases</a>


</h2>
					 					</div>
    				<!-- emergency -->
<div id="emergencyContainer">
	<!--
	<div class="alert alert-error en">
		<b>Attention!</b> Uncomment this section and place the emergency message here.
	</div>
	<div class="alert alert-error esp">
		<b>&#161;Atenci&#243;n!</b> Elimine el comentario de esta secci&#243;n y colocar el mensaje de emergencia aqu&#237;.
	</div>	
	-->
</div>

<!-- no script -->
<noscript>
	<div class="alert alert-block"> Note: Javascript is disabled or is not supported by your browser. For this reason, some items on this page will be unavailable. For more information about this message, please visit this page: <a href="../../../other/about_cdcgov.html">About CDC.gov</a>.</div>
</noscript>
<script>if (typeof page_timing !== 'undefined') { page_timing.noscript_load = Date.now(); }</script>
     			</div>
    		</header>
    		<div class="container">				
                <div id="content">
					<div class="row">
        				<!-- left nav -->
        				<div id="nav-container" class="hidden-one hidden-two span5">
    						<nav id="left" class="hidden-one hidden-two">
    							



<h3><a href="index.html">Surveillance Manual Home</a></h3>

<ul id="nav-primary">
<li><a href="front-portion.html">Front Matter</a></li>

<li><a href="chapters.html">Chapters</a>
<ul>
<li><a href="chpt01-dip.html">Chapter 1: Diphtheria</a></li>

<li><a href="chpt02-hib.html">Chapter 2: Haemophilus influenzae type b</a></li>

<li><a href="chpt03-hepa.html">Chapter 3: Hepatitis A</a></li>

<li><a href="chpt04-hepb.html">Chapter 4: Hepatitis B</a></li>

<li><a href="chpt05-hpv.html">Chapter 5: HPV</a></li>

<li><a href="chpt06-influenza.html">Chapter 6: Influenza</a></li>

<li><a href="chpt07-measles.html">Chapter 7: Measles</a></li>

<li><a href="chpt08-mening.html">Chapter 8: Meningococcal</a></li>

<li><a href="chpt09-mumps.html">Chapter 9: Mumps</a></li>

<li><a href="chpt10-pertussis.html">Chapter 10: Pertussis</a></li>

<li><a href="chpt11-pneumo.html">Chapter 11: Pneumococcal</a></li>

<li><a href="chpt12-polio.html">Chapter 12: Polio</a></li>

<li><a href="chpt13-rotavirus.html">Chapter 13: Rotavirus</a></li>

<li><a href="chpt14-rubella.html">Chapter 14: Rubella</a></li>

<li><a href="chpt15-crs.html">Chapter 15: Congenital Rubella Syndrome</a></li>

<li><a href="chpt16-tetanus.html">Chapter 16: Tetanus</a></li>

<li><a href="chpt17-varicella.html">Chapter 17: Varicella</a></li>

<li><a href="chpt18-surv-indicators.html">Chapter 18: Surveillance Indicators</a></li>

<li><a href="chpt19-enhancing-surv.html">Chapter 19: Enhancing Surveillance</a></li>

<li><a href="chpt20-analysis-surv.html">Chapter 20: Analysis of Surveillance Data</a></li>

<li><a href="chpt21-surv-adverse-events.html">Chapter 21: Surveillance for Adverse Events Following Vaccination</a></li>

<li><a href="chpt22-lab-support.html">Chapter 22: Laboratory Support for the Surveillance of Vaccine-Preventable Diseases</a></li>

<li><a href="chpt23-natl-surv-vpd.html">Chapter 23: National Surveillance of Vaccine-Preventable Diseases</a></li>

<li><a href="chpt24-state-specific-surv.html">Chapter 24: State-Specific Surveillance of Vaccine-Preventable Diseases</a></li>
</ul>
</li>

<li><a href="appendix.html">Appendices</a></li>
</ul>


    						</nav>
    						<div class="nav-related">
							


<div class="module-typeG emailupdates">
<span class="sprite-24-govd-icon"><!-- span --></span> <h4>Get Email Updates</h4>
<p>To receive email updates about this page, enter your email address:</p>
<form action="https://public.govdelivery.com/accounts/USCDC/subscribers/qualify" name="govdelivery">
<fieldset>
<input name="topic_id" type="hidden" value="USCDC_11_40">
<label>
<span class="hidden">Enter Email Address</span>
<input class="email" name="email" type="text" value="">
</label>
<a class="explain" href="../../../emailupdates/index.html">What's this?</a>
<a class="button" href="chpt04-hepb.html#;">Submit</a>

<noscript>&lt;a class="explain" href="https://www.cdc.gov/emailupdates/"&gt;What's this?&lt;/a&gt; &lt;label&gt;&lt;span class="hidden"&gt;Submit Button&lt;/span&gt; &lt;input class="button submit" name="commit" type="submit" value="Submit" /&gt;&lt;/label&gt;</noscript>
</fieldset>
</form>
</div>

    						



	    <div class="module-typeH">
		<h3>Related Links</h3>
		<div>
																	<ul class="list-block">																														<li>					
<a href="../../index.html">Vaccines &amp; Immunizations</a>					</li>										</ul>														</div>
	</div>
	  



							



							</div>    						    				
        				</div>
        				<div id="featureArea">
    						<div class="span19">
    							



    						</div>
        				</div>						
    					<div class="breadcrumbs hidden-one span19">
    						


<div class="bread-crumb hidden-one"></div>

    					</div>
						<div class="span19 pagetitle">	
    						    							<div class='syndicate'>
    						    						    							<div class='mSyndicate'>
    																					<h1>Chapter 4: Hepatitis B </h1>
															    						    							</div>
    						    						    							</div>
    												</div>
						<div id="share-bar" class="span19">		
    						<div class="socialmediabar">
								<div class="row">
            						<div class="hidden-one pull-right">
        								            							            							<div class="pageoptionsContainer formatOptions formatOptionsOff"><span id="po-format-label" class="select-label">Format:</span><div id="po-format" class="format pageoptions pull-right"><div class="select-box"><a href="chpt04-hepb.html#">Select one</a><span class="icon-angle-down pull-right poarrow"></span></div><ul class="drop-down" aria-labelledby="po-format-label"><li>
        			    	<a class="noDecoration" href="https://www.cdc.gov/vaccines/pubs/surv-manual/chpt04-hepb.pdf" target="_blank"><span class="sprite-16-pdf"></span> PDF [462 KB]</a>
      </li></ul></div></div>            						</div>	
    								<div class="span8">
    									<div id="socialMediaShareContainer">
	<div class="share_container noLinking">
	 	<a class="share_button_facebook" title="Facebook" href="chpt04-hepb.html#"><span class="tp-sr-only">Recommend on Facebook</span><span id="share_facebook" class="facebookRecommend"> </span></a>
	 	<a class="share_button_twitter" title="Twitter" href="chpt04-hepb.html#"><span class="tp-sr-only">Tweet</span><span id="share_twitter" class="twitterTweet"> </span></a>
		<a class="share_button" href="chpt04-hepb.html#socialMediaShareContainer" ><img src="../../../TemplatePackage/3.0/images/social/addthis-32.png" alt="Share" /><span class="shareButtonEn tp-sr-only" aria-label="Share">Share</span><span class="shareButtonEs tp-sr-only" aria-label="Compartir">Compartir</span></a>
	</div>
</div>

<!-- target anchor for return to top feature in VP1 -->
<a id="content-start" tabindex="-1"></a>
    								</div>
								</div>
    						</div>
    					</div>	
    					<!-- body -->
    					<div id="body" class="span19">
    						<div id="contentArea" >								
        						        														
			<div class="span6 pull-right">
    		<div id="onthispage2" class="module-typeF">
				    			<h4>On this Page</h4>				    			<ul class="list-bullet">
    				    				<li><a href="chpt04-hepb.html#description">Disease Description</a></li>    				    				<li><a href="chpt04-hepb.html#background">Background</a></li>    				    				<li><a href="chpt04-hepb.html#identification">Importance of Rapid Identification</a></li>    				    				<li><a href="chpt04-hepb.html#surveillance">Importance of Surveillance</a></li>    				    				<li><a href="chpt04-hepb.html#goals">Disease Reduction Goals</a></li>    				    				<li><a href="chpt04-hepb.html#case">Case Definition</a></li>    				    				<li><a href="chpt04-hepb.html#laboratory">Laboratory Testing</a></li>    				    				<li><a href="chpt04-hepb.html#reporting">Reporting</a></li>    				    				<li><a href="chpt04-hepb.html#vaccination">Vaccination</a></li>    				    				<li><a href="chpt04-hepb.html#enhancing-surveillance">Enhancing Surveillance</a></li>    				    				<li><a href="chpt04-hepb.html#case-investigation">Case Investigation</a></li>    				    			</ul>
    		</div>
		</div>
	  								        						                                                                                            					            						<div class='syndicate'>
            					            					            						<div class='mSyndicate'>
            					            					        							
<h3>Manual for the Surveillance of Vaccine-Preventable Diseases</h3>

<p class="printerfriendly-left"><a href="https://www.cdc.gov/vaccines/pubs/surv-manual/chpt04-hepb.pdf">Printer friendly version [13 pages]</a></p>

<p><span class="bold">Authors:</span>Lyn Finelli, DrPH and Beth P. Bell, MD, MPH</p>

<h2><a class="onThisPageAnchor" id="description" name="description" title="Disease Description"> </a>Disease Description</h2>

<p>Hepatitis B is caused by infection with the hepatitis B virus (HBV), a double-stranded DNA virus of the family hepadnaviridae. HBV replicates in the liver and causes both acute and chronic hepatitis. Although the highest concentrations of virus are found in blood, other body fluids, such as semen and saliva, also have been demonstrated to contain HBV. Thus, HBV is predominantly a blood and sexually transmitted infection and is transmitted by percutaneous and mucosal exposure to infectious body fluids.</p>

<p>The incubation period for acute hepatitis B ranges from 45 to 160 days (average 120 days). The clinical manifestations of acute HBV infection are age dependent. Infants, young children (younger than 10 years of age), and immunosuppressed adults with newly acquired HBV infection are usually asymptomatic. <a href="chpt04-hepb.html#f1">[1]</a> Older children and adults are symptomatic in 30%-50% of infections. When present, clinical symptoms and signs might include anorexia, malaise, nausea, vomiting, abdominal pain, jaundice, dark urine, and clay-colored or light stools. Occasionally, extrahepatic manifestations occur and include skin rashes, arthralgias, and arthritis. Fulminant hepatitis occurs with a case-fatality rate of 0.5%-1%.</p>

<p>From 2003-2008, there was an estimated 38,000-73,000 new HBV infections annually in the U.S. <a href="chpt04-hepb.html#f2">[2]</a> Each year about 600,000 HBV-related deaths occur worldwide. <a href="chpt04-hepb.html#f3">[3]</a> Among adults with normal immune status, most (94%-98%) recover completely from newly acquired HBV infections, eliminating virus from the blood and producing neutralizing antibody that creates immunity from future infection. In infants, young children, and immunosuppressed persons, most newly acquired HBV infections result in chronic infection. <a href="chpt04-hepb.html#f4">[4]</a> Infants are at greatest risk, with a 90% chance of developing chronic infection if infected at birth. Although the consequences of acute hepatitis B can be severe, most of the serious sequelae occur in persons in whom chronic infection developed. Persons who acquire chronic HBV infection as infants or young children are often asymptomatic; however, chronic liver disease develops in two-thirds of these persons, and approximately 15%-25% die prematurely from cirrhosis or liver cancer. Persons with chronic HBV infection are often detected in screening programs, such as those for blood donors, pregnant women, and refugees. Persons with chronic HBV infection are a major reservoir for transmission of HBV infections. Any person testing positive for hepatitis B surface antigen (HBsAg) is potentially infectious to both household and sexual contacts.</p>

<h2><a class="onThisPageAnchor" id="background" name="background" title="Background"> </a>Background</h2>

<p>Each year during the 1970s and 1980s, an estimated 200,000-300,000 persons worldwide were newly infected with HBV. Until recently, hepatitis B was one of the most frequently reported vaccine-preventable diseases in the United States, with 15,000-20,000 cases reported annually to the National Notifiable Diseases Surveillance System (NNDSS). Since 1985, a steady decline has occurred in the number of cases of acute hepatitis B reported to the NNDSS. In 2007, approximately 4,500 cases of acute hepatitis B were reported, which after correcting for underreporting and asymptomatic infections, represented an estimated 43,000 new cases.<a href="chpt04-hepb.html#f2">[2]</a> Based on testing from the National Health and Nutrition Examination Survey, the age-adjusted prevalence of hepatitis B core antibody, which indicates past or present infection, in the US population decreased from 5.4% in 1988-1994 to 4.7% during 1999-2006 among persons aged 6 years and older. The age adjusted prevalence of hepatitis B core antibody and hepatitis B surface antigen together, which indicates chronic active HBV infection, decreased from 0.38% to 0.27% among persons aged 6 years and older during the same time periods.<a href="chpt04-hepb.html#f3">[3]</a> An estimated 730,000 US adults had chronic active hepatitis B during 1999-2006.<a href="chpt04-hepb.html#f3">[3]</a></p>

<p>The extent to which children acquire HBV infection in the United States has not been appreciated, primarily because most infections in this age group are asymptomatic. In the United States, approximately 24,000 HBsAg-positive women gave birth in 2005. Without postexposure prophylaxis to prevent perinatal HBV infection, it is estimated that 12,000 infants and children would be infected with HBV annually. Furthermore, before the implementation of universal infant hepatitis B immunization, an additional 16,000 children younger than 10 years old were infected annually in the United States through exposure to HBsAg-positive household members or community contacts. Populations with the highest rates of these early childhood infections included Alaska Natives, children of Pacific Islander parents, and children of first-generation immigrants from countries where HBV is of high or intermediate endemicity.<a href="chpt04-hepb.html#f5">[5-8]</a></p>

<p>Screening of all pregnant women for HBsAg to identify infants requiring postexposure prophylaxis has been recommended since 1988, universal childhood hepatitis B immunization since 1991, universal adolescent hepatitis B immunization since 1995,<a href="chpt04-hepb.html#f9">[9, 10]</a> and universal hepatitis B birth dose administration since 2005. In the United States, without postexposure prophylaxis, HBV would annually infect 12,000 infants; without routine childhood immunization, 16,000 children would be infected.</p>

<p>Among persons who reported risk behaviors/exposures in 2007, the most frequently reported risk behavior/exposure for acute, symptomatic hepatitis B was multiple sex partners (38%), followed by men who have sex with men (MSM) (11%) and sexual contact with a person known to have hepatitis B (6%). Injection drug use (IDU) was reported for 15% of persons.<a href="chpt04-hepb.html#f11">[11]</a> Although up to 25% of persons with newly acquired hepatitis B do not report a source for their infection, many of these persons have had a past history of high-risk sex or drug behaviors. Furthermore, more than half of persons with newly acquired hepatitis B were previously seen in medical settings where hepatitis B vaccine is routinely recommended, such as sexually transmitted disease (STD) treatment clinics. Thus, programs to vaccinate older adolescents and adults at increased risk for HBV infection need to be strengthened nationwide in order to have a significant impact on reducing HBV transmission in the next 2 decades.</p>

<p><span class="toTop"><span class="icon-angle-up"><!-- --></span>&#160;<a href="chpt04-hepb.html#">Top of Page</a></span></p>

<h2><a class="onThisPageAnchor" id="identification" name="identification" title="Importance of Rapid Identification"> </a>Importance of Rapid Identification</h2>

<p>Rapid identification and prompt reporting of cases of acute hepatitis B is important because measures such as postexposure prophylaxis can be taken to prevent transmission to other persons. Although outbreaks of hepatitis B are unusual, rapid recognition allows for identification of the source and prevention of further transmission. In addition, identification of risk behaviors/exposures for infection provides a means to assess the effectiveness of hepatitis B immunization activities in the community and identify missed opportunities for immunization.</p>

<p>In most states, HBsAg positivity is a laboratory reportable condition. Reporting of HBsAg-positive persons facilitates timely immunization of contacts. For HBsAg-positive pregnant women, reporting allows for initiation of case management to ensure prevention of perinatal HBV transmission (see "Postexposure prophylaxis" below). In 2003, chronic HBV infection became nationally notifiable and is reportable by state health departments to the NNDSS. All states are encouraged to report chronic hepatitis B infection. States should develop registries of persons with HBsAg-positive laboratory results to facilitate postexposure prophylaxis of contacts and reporting to NNDSS (see "Registries/databases for HBsAg-positive persons" below).</p>

<h3>Postexposure prophylaxis</h3>

<p>Hepatitis B immune globulin (HBIG) is prepared from human plasma known to contain a high titer of antibody to HBsAg (anti-HBs). The plasma from which HBIG is prepared is screened for HBsAg, hepatitis C virus (HCV), and human immunodeficiency virus, and since 1999, all products available in the United States have been manufactured by methods that inactivate HCV and other viruses. A regimen combining HBIG and hepatitis B vaccine is 85%-95% effective in preventing HBV infection when administered at birth to infants born to HBsAg-positive mothers. Regimens involving either multiple doses of HBIG alone or the hepatitis B vaccine series alone are 70%-75% effective in preventing HBV infection. It is recommended that HBIG should be given as soon as possible, after exposure to hepatitis B. Although the postexposure efficacy of the combination of HBIG and the hepatitis B vaccine series has not been evaluated for occupational or sexual exposures, it can be presumed that the increased efficacy of this regimen observed in the perinatal setting compared with HBIG alone would apply to these exposures.</p>

<p>Postexposure prophylaxis with HBIG and hepatitis B vaccine should be given to infants born to HBsAg-positive mothers, unvaccinated infants whose mothers or primary caregivers have acute hepatitis B, sexual contacts of persons with hepatitis B, and healthcare workers after occupational exposure to HBsAg-positive blood depending on their vaccination and vaccine response status. Household and sexual contacts of persons with chronic HBV infection should be vaccinated.</p>

<h2><a class="onThisPageAnchor" id="surveillance" name="surveillance" title="Importance of Surveillance"> </a>Importance of Surveillance</h2>

<p>Disease surveillance is used to 1) identify contacts of case-patients who require postexposure prophylaxis; 2) detect outbreaks; 3) identify infected persons who need counseling and referral for medical management; 4) monitor disease incidence and prevalence; and 5) determine the epidemiologic characteristics of infected persons, including the source of their infection, to assess and reduce missed opportunities for vaccination.</p>

<p><span class="toTop"><span class="icon-angle-up"><!-- --></span>&#160;<a href="chpt04-hepb.html#">Top of Page</a></span></p>

<h2><a class="onThisPageAnchor" id="goals" name="goals" title="Disease Reduction Goals"> </a>Disease Reduction Goals</h2>

<p>The primary goal of hepatitis B vaccination is to prevent chronic HBV infection. However, because such a high proportion of persons with chronic HBV infection are asymptomatic and the consequences are not seen for many years, monitoring the direct impact of prevention programs on the prevalence of chronic infection is difficult. Consequently, the disease reduction goals that have been established for hepatitis B are a combination of process and disease outcome measures. Because most HBV infections among children younger than 10 years of age are asymptomatic, programs targeting infants and children are best evaluated by measuring vaccination coverage and not by measuring reduction in acute infection. In older age groups, monitoring the incidence of acute disease as well as measuring vaccine coverage levels provides data useful for measuring the effectiveness of prevention programs.</p>

<p><em>Healthy People 2020</em> disease reduction goals have been established for achieving the prevention of HBV transmission in the United States. Disease reduction goals for infants and children include reducing the estimated number of chronic HBV infections in infants and young children to 400 cases and the number of new hepatitis B cases reported among persons 2-18 years of age to zero cases. Healthy People 2020 vaccination goals for infants and children include setting a target coverage level for infants age 0-3 days receiving the initial birth dose of hepatitis B vaccine to 85% and for children age 19-35 months completing the three-dose hepatitis B vaccination series to 90%.<a href="chpt04-hepb.html#f12">[12]</a></p>

<p>Disease reduction goals for adults include reducing the rate of acute hepatitis B to 1.5 cases per 100,000 in persons age 19 years and older. Among adults in high-risk groups, disease reduction goals include reducing the number of cases of acute hepatitis B to 215 cases in injection-drug users and to 45 new infections among men who have sex with men.<a href="chpt04-hepb.html#f12">[12]</a></p>

<h2><a class="onThisPageAnchor" id="case" name="case" title="Case Definition"> </a>Case Definition</h2>

<p>The following case definitions for acute hepatitis B, chronic hepatitis B virus infection and perinatal HBV infection have been adopted by the Council of State and Territorial Epidemiologists. <a href="chpt04-hepb.html#f13">[13]</a></p>

<h3>Hepatitis B, acute (effective 2000)</h3>

<h4>Clinical case definition</h4>

<p>An acute illness with</p>

<ul>
<li>A discrete onset of symptoms, and</li>

<li>Jaundice or elevated serum aminotransferase levels</li>
</ul>

<h4>Laboratory criteria for diagnosis</h4>

<ul>
<li>IgM antibody to hepatitis B core antigen (anti-HBc) positive or hepatitis B surface antigen (HBsAg) positive</li>

<li>IgM anti-HAV negative (if done)</li>
</ul>

<h4>Case classification</h4>

<p><span class="bold"><em>Confirmed</em>:</span> A case that meets the clinical case definition and is laboratory confirmed.</p>

<h3>Chronic hepatitis B virus infection (effective 2007)</h3>

<h4>Clinical description</h4>

<p>Persons with chronic HBV infection may have no evidence of liver disease or may have a spectrum of disease ranging from chronic hepatitis to cirrhosis or liver cancer. Persons with chronic infection may be asymptomatic.</p>

<h4>Laboratory criteria for diagnosis</h4>

<ul>
<li>IgM anti-HBc negative AND a positive result on one of the following tests: HBsAg, HBeAg, or HBV DNA <span class="bold">OR</span></li>

<li>HBsAg positive or HBV DNA positive or HBeAg positive two times at least 6 months apart (Any combination of these tests performed 6 months apart is acceptable.)</li>
</ul>

<h4>Case classification</h4>

<p><span class="bold"><em>Confirmed</em>:</span> a case that meets either laboratory criterion for diagnosis</p>

<p><span class="bold"><em>Probable</em>:</span> a case with a single HBsAg-positive or HBV DNA-positive or HBeAg-positive laboratory result when no IgM anti-HBc results are available</p>

<p><span class="bold"><em>Comment</em>:</span> Multiple laboratory tests indicative of chronic HBV infection may be performed simultaneously on the same patient specimen as part of a “hepatitis panel.” Testing performed in this manner may lead to seemingly discordant results, e.g., HBsAg negative AND HBV DNA positive. For purposes of this case definition, any positive result among the three laboratory tests mentioned above is acceptable, regardless of other testing results. Negative HBeAg results and HBV DNA levels below positive cutoff level do not confirm the absence of HBV infection.</p>

<h3>Perinatal hepatitis B virus infection (effective 1995)</h3>

<h4>Clinical description</h4>

<p>Perinatal hepatitis B in the newborn may range from asymptomatic to fulminant hepatitis.</p>

<h4>Laboratory criteria for diagnosis</h4>

<p>Hepatitis B surface antigen (HBsAg) positive</p>

<h4>Case classification</h4>

<p>HBsAg positivity in any infant aged &#62;1-24 months who was born in the United States or in U.S. territories to an HBsAg-positive mother</p>

<p><span class="bold"><em>Comment</em>:</span> Infants born to HBsAg-positive mothers should receive HBIG and the first dose of hepatitis B vaccine within 12 hours of birth, followed by the second and third doses of vaccine at 1 and 6 months of age, respectively, if receiving the single-antigen vaccine. Dosage and scheduling will be different if the infant received a combination vaccine (see Table 1). Postvaccination testing for HBsAg and anti-HBs (antibody to HBsAg) is recommended from 3 to 6 months following completion of the vaccine series. If HBIG and the initial dose of vaccine are delayed for more than 1 month after birth, testing for HBsAg may determine if the infant is already infected.</p>

<p><span class="toTop"><span class="icon-angle-up"><!-- --></span>&#160;<a href="chpt04-hepb.html#">Top of Page</a></span></p>

<h4><a id="t1" name="t1"> </a>Table 1. Hepatitis B combination vaccine schedule for newborn infants born to HBsAg positive mothers</h4>

<table class="opt-in table table-bordered"><thead class="primary-bg-color">
<tr>
<th id="t1h1">Single antigen* combination vaccine<br />
Dose</th>
<th id="t1h2">Single antigen* combination vaccine<br />
Age</th>
</tr>

</thead>
<tr>
<td headers="t1h1">1</td>
<td headers="t1h2">Birth ( &#60; 12 hrs)</td>
</tr>

<tr>
<td headers="t1h1">HBIG</td>
<td headers="t1h2">Birth ( &#60; 12 hrs)</td>
</tr>

<tr>
<td headers="t1h1">2</td>
<td headers="t1h2">2 mos</td>
</tr>

<tr>
<td headers="t1h1">3</td>
<td headers="t1h2">4 mos</td>
</tr>

<tr>
<td headers="t1h1">4 mos</td>
<td headers="t1h2">6 mos (Pediarix) or 12-15 mos (Comvax)</td>
</tr>
</table>

<p class="bold smallFontSize">* Recombivax HB or Engerix-B should be used for the birth dose. Comvax and Pediarix cannot be administered at birth or before age 6 weeks.<br />
Source: CDC. A comprehensive strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP); Part 1: Immunization of infants, children and adolescents. MMWR 2005; 54(No. RR-16).</p>

<hr />
<h2><a class="onThisPageAnchor" id="laboratory" name="laboratory" title="Laboratory Testing"> </a>Laboratory Testing</h2>

<p>Several specific and well-defined antigen-antibody systems are associated with HBV infection, including hepatitis B surface antigen (HBsAg) and antibody to HBsAg (anti-HBs); hepatitis B core antigen (HBcAg) and antibody to HBcAg (anti-HBc); and hepatitis B e antigen (HBeAg) and antibody to HBeAg (anti-HBe). Serologic assays are commercially available for all of these except HBcAg because no free HBcAg circulates in blood. One or more of these serologic markers are present in the blood during different phases of HBV infection (Table 2). Subtyping of HBsAg has occasionally been used to investigate outbreaks of hepatitis B, but this procedure is not routinely available in commercial laboratories.</p>

<h4><a id="t2" name="t2"> </a>Table 2. Interpretation of serologic test results for hepatitis B virus infection</h4>

<table class="opt-in table table-bordered"><thead class="primary-bg-color">
<tr>
<th id="t2h1">Serologic Markers<br />
HBsAg* Serologic Marker</th>
<th id="t2h2">Serologic Markers<br />
Total Anti-HBc† Serologic Marker</th>
<th id="t2h3">Serologic Markers<br />
IgM Anti-HBc§ Serologic Marker</th>
<th id="t2h4">Serologic Markers<br />
Anti-HBs¶ Serologic Marker</th>
<th id="t2h5">Interpretation</th>
</tr>

</thead>
<tr>
<td headers="t2h1">-</td>
<td headers="t2h2">-</td>
<td headers="t2h3">-</td>
<td headers="t2h4">-</td>
<td headers="t2h5">Susceptible, never infected</td>
</tr>

<tr>
<td headers="t2h1">+</td>
<td headers="t2h2">-</td>
<td headers="t2h3">-</td>
<td headers="t2h4">-</td>
<td headers="t2h5">Acute infection, early incubation**</td>
</tr>

<tr>
<td headers="t2h1">+</td>
<td headers="t2h2">+</td>
<td headers="t2h3">+</td>
<td headers="t2h4">-</td>
<td headers="t2h5">Acute infection</td>
</tr>

<tr>
<td headers="t2h1">-</td>
<td headers="t2h2">+</td>
<td headers="t2h3">+</td>
<td headers="t2h4">-</td>
<td headers="t2h5">Acute resolving infection</td>
</tr>

<tr>
<td headers="t2h1">-</td>
<td headers="t2h2">+</td>
<td headers="t2h3">-</td>
<td headers="t2h4">+</td>
<td headers="t2h5">Past infection, recovered and immune</td>
</tr>

<tr>
<td headers="t2h1">+</td>
<td headers="t2h2">+</td>
<td headers="t2h3">-</td>
<td headers="t2h4">-</td>
<td headers="t2h5">Chronic infection</td>
</tr>

<tr>
<td headers="t2h1">-</td>
<td headers="t2h2">+</td>
<td headers="t2h3">-</td>
<td headers="t2h4">-</td>
<td headers="t2h5">False positive (i.e., susceptible), past infection, or "low level" chronic infection</td>
</tr>

<tr>
<td headers="t2h1">-</td>
<td headers="t2h2">-</td>
<td headers="t2h3">-</td>
<td headers="t2h4">+</td>
<td headers="t2h5">Immune if titer is &#62;10 mIU/ml</td>
</tr>
</table>

<p class="bold smallFontSize">* Hepatitis B surface antigen<br />
† Antibody to hepatitis B core antigen<br />
§ Immunoglobulin M<br />
¶ Antibody to hepatitis B surface antigen<br />
** Transient HBsAg positivity (lasting &#60;18 days) might be detected in some patients during vaccination.</p>

<hr />
<p>The presence of HBsAg is an indication of ongoing HBV infection and the potential to spread the infection. In persons newly infected, HBsAg is present in serum 30-60 days after exposure to HBV and persists for variable periods. Anti-HBc develops in HBV infections, appearing at onset of symptoms or in liver test abnormalities in acute HBV infection, rising rapidly to high levels, and persisting for life. The presence of the immunoglobulin M (IgM) class of anti-HBc, which persists for approximately 6 months, distinguishes acute or recently acquired infection. However, among infected infants, passively transferred maternal anti-HBc may persist beyond the age of 12 months, and IgM anti-HBc may not be present in newly infected children younger than 2 years of age, especially if they acquired their infection through perinatal transmission.</p>

<p>In persons who recover from HBV infection, HBsAg is eliminated from the blood system in 2-3 months, and anti-HBs develops during convalescence. The presence of anti-HBs indicates immunity from HBV infection. After recovery from natural infection, most persons will be positive for both anti-HBs and anti-HBc, whereas only anti-HBs develops in persons who are successfully vaccinated against hepatitis B. Additionally, anti-HBs can be present in persons who have received HBIG. Persons who do not recover from HBV infection and become chronically infected remain positive for HBsAg (and anti-HBc), although a small proportion (0.3% per year) eventually clear HBsAg and might develop anti-HBs.</p>

<h3>Special laboratory studies</h3>

<p>Molecular virologic methods such as polymerase chain reaction (PCR)-based assays are often used to amplify and sequence viral genomes. In conjunction with epidemiologic studies, these assays may be helpful for investigating common-source outbreaks of hepatitis B. In addition, these assays are essential for detecting the emergence of potential vaccine-resistant strains. Healthcare professionals with questions about molecular virologic methods or those who identify HBsAg-positive events among vaccinated persons should consult with their state health department or the Epidemiology and Surveillance Branch, Division of Viral Hepatitis, CDC, 404-718-8500.</p>

<p>For additional information on laboratory support for surveillance of vaccine-preventable diseases, see <a href="chpt22-lab-support.html">Chapter 22, "Laboratory Support for Surveillance of Vaccine-preventable Diseases"</a>.</p>

<h2><a class="onThisPageAnchor" id="reporting" name="reporting" title="Reporting"> </a>Reporting</h2>

<p>In the United States, case reports of viral hepatitis are classified as hepatitis A, acute hepatitis B, acute hepatitis C, perinatal HBV infection, chronic HBV infection and hepatitis C, past or present. Serologic testing is necessary to determine the etiology of viral hepatitis, and case reports should be based on laboratory confirmation (see Section VII). Each state and territory has a list of reportable diseases and conditions of public health importance.<a href="chpt04-hepb.html#f14">[14]</a> These diseases and conditions that are to be reported and describe those persons or groups who are responsible for reporting, such as healthcare providers, hospitals, laboratories, and other institutions. Persons reporting these conditions should contact their state health department for state-specific reporting requirements.</p>

<h3>Reporting to CDC</h3>

<p>Case reports of acute hepatitis B, chronic HBV infection, perinatal HBV infection, and other reportable diseases are transmitted by the state health department weekly to CDC via the National Electronic Telecommunications System for Surveillance (NETSS). The NETSS core data elements include basic information (excluding personal identifiers)—age, race/ethnicity, sex, date of onset, date of report, county of residence. The NETSS extended data elements include clinical data, laboratory results, and exposure history. However, completeness of reporting of these extended data elements is often incomplete. In 2007, 52% of acute, symptomatic hepatitis B cases were reported in the United States with unavailable risk exposure/behavior information.<a href="chpt04-hepb.html#f11">[11]</a> The Division of Viral Hepatitis has developed an extended Data Collection Worksheet to collect information about symptoms, risk behavior/exposures and serologic data <a href="https://www.cdc.gov/vaccines/pubs/surv-manual/appx/appendix06-hepatitis-wrsht.pdf">(Appendix 6, "Viral Hepatitis Case Report" [6 pages].</a>) This worksheet can be used for case investigation and data can be directly entered into the state’s electronic reporting system. Sites reporting through the National Electronic Diseases Surveillance System (NEDSS)15 NEDSS-compatible, and Emerging Infections Program <a href="chpt04-hepb.html#f16">[16]</a> (Enhanced Hepatitis Surveillance) infrastructure collect data elements using this worksheet.</p>

<p><span class="toTop"><span class="icon-angle-up"><!-- --></span>&#160;<a href="chpt04-hepb.html#">Top of Page</a></span></p>

<h2><a class="onThisPageAnchor" id="vaccination" name="vaccination" title="Vaccination"> </a>Vaccination</h2>

<p>Infants born to HBsAg-positive women should be administered by intramuscular injection hepatitis B immune globulin (HBIG; for hepatitis B postexposure prophylaxis) and the first dose of hepatitis B vaccine within 12 hours of birth. This combination also should be administered as soon as possible to unvaccinated infants whose primary caregivers have acute hepatitis B, unvaccinated healthcare personnel after occupational exposure, and sex partners of persons with acute hepatitis B . Studies are limited on the maximum interval after exposure during which postexposure prophylaxis is effective, but the interval is unlikely to exceed 7 days for percutaneous exposures and 14 days for sexual exposures. Exact treatment varies depending on source status and vaccination status. For infants born to women positive for HBsAg, the dose of HBIG is 0.5 mL. For all other applications, the dose is 0.06 mL/kg.<a href="chpt04-hepb.html#f17">[17]</a></p>

<h3>Hepatitis B vaccine</h3>

<p>Two single-antigen recombinant hepatitis B vaccines are commercially available, Recombivax HB® (Merck &#38; Company, Inc.) and Engerix-B® (GlaxoSmithKline). Recombivax HB contains 5-40 μg of HBsAg protein per milliliter, depending on the formulation, whereas Engerix-B contains 20 μg/mL. Both vaccines are licensed for persons of all ages (Table 3).</p>

<h4><a id="t3" name="t3"> </a>Table 3. Recommended doses of currently licensed combination hepatitis B vaccines*</h4>

<table class="opt-in table table-bordered"><thead class="primary-bg-color">
<tr>
<th id="t3h1">Group</th>
<th id="t3h2">Recombivax HB*<br />
Dose (µg)</th>
<th id="t3h3">Recombivax HB*<br />
Volume (mL)</th>
<th id="t3h4">Engerix-B*<br />
Dose (µg)</th>
<th id="t3h5">Engerix-B*<br />
Volume (mL)</th>
</tr>

</thead>
<tr>
<td headers="t3h1"><span class="bold">Infants, children and adolescents<br />
younger than 20 years of age</span></td>
<td headers="t3h2">5</td>
<td headers="t3h3">(0.5)</td>
<td headers="t3h4">&#160;</td>
<td headers="t3h5">(0.5)</td>
</tr>

<tr>
<td headers="t3h1"><span class="bold">Adolescents 11-15 years†</span><br />
(adult formulation administered on 2-dose schedule)&#62;</td>
<td headers="t3h2">10</td>
<td headers="t3h3">(1.0)</td>
<td headers="t3h4">&#160;</td>
<td headers="t3h5">&#160;</td>
</tr>

<tr>
<td headers="t3h1"><span class="bold">Adults 20 years of age or older</span></td>
<td headers="t3h2">10</td>
<td headers="t3h3">(1.0)</td>
<td headers="t3h4">20</td>
<td headers="t3h5">(1.0)</td>
</tr>

<tr>
<td headers="t3h1"><span class="bold">Hemodialysis patients and other immunocompromised persons</span></td>
<td headers="t3h2">40</td>
<td headers="t3h3">(1.0)§</td>
<td headers="t3h4">40</td>
<td headers="t3h5">(2.0)¶</td>
</tr>
</table>

<p class="bold smallFontSize">* Both vaccines are routinely administered in three-dose series. Engerix-B also has been licensed for a four-dose series administered at 0, 1, 2, and 12 months.<br />
† Two-dose schedule for adolescents using adult dose of Recombivax HB has been approved by ACIP, administered at 0, 4-6 months.<br />
§ Special formulation administered on a 3-dose schedule at 0, 1, and 6 months.<br />
¶ Two 1.0-mL doses administered at one site in a four-dose schedule at 0, 1, 2, and 6 months.<br />
&#160;</p>

<hr />
<p>Twinrix® (GlaxoSmithKline), a combination of hepatitis A and B vaccine, is also available for use in persons aged 18 years and older. Twinrix consists of the antigenic components used in HAVRIX®(hepatitis A vaccine) and Engerix-B. In addition, there are two combination vaccines (Comvax® [Merck] and Pediarix® [GlaxoSmithKline]) that are used for vaccination of infants and young children. Comvax contains recombinant HBsAg and Haemophilus influenzae type b (Hib) polyribosylribitol phosphate conjugated vaccine. Pediarix contains recombinant HBsAg, diphtheria and tetanus toxoids and acellular pertussis adsorbed (DTaP), and inactivated poliovirus (IPV). However, these combination vaccines may not be administered to infants younger than 6 weeks of age (with exception of Twinrix®); only single-antigen hepatitis B vaccine may be used for the birth dose. Administration of four-dose hepatitis B vaccine schedules, including schedules with a birth dose followed by a combination vaccine series, is permissible (Table 4).</p>

<h4><a id="t4" name="t4"> </a>Table 4. Recommended doses of currently licensed combination hepatitis B vaccines*</h4>

<table class="opt-in table table-bordered"><thead class="primary-bg-color">
<tr>
<th id="t4h1">Group</th>
<th id="t4h2">COMVAX<br />
Dose<br />
(µg) § ¶</th>
<th id="t4h3">COMVAX<br />
Volume<br />
(mL)</th>
<th id="t4h4">PEDIARIX<br />
Dose<br />
(µg) § **</th>
<th id="t4h5">PEDIARIX<br />
Volume<br />
(mL)</th>
<th id="t4h6">TWINRIX†<br />
Dose<br />
(µg)§ ††</th>
<th id="t4h7">TWINRIX†<br />
Volume<br />
(mL)</th>
</tr>

</thead>
<tr>
<td headers="t4h1"><span class="bold">Infant (less than 1 year)—</span><br />
Mother HBsAg negative</td>
<td headers="t4h2">5</td>
<td headers="t4h3">0.5</td>
<td headers="t4h4">10</td>
<td headers="t4h5">0.5</td>
<td headers="t4h6">NA</td>
<td headers="t4h7">NA</td>
</tr>

<tr>
<td headers="t4h1"><span class="bold">Infant—</span> Mother HBsAg positive</td>
<td headers="t4h2">5</td>
<td headers="t4h3">0.5</td>
<td headers="t4h4">10</td>
<td headers="t4h5">0.5</td>
<td headers="t4h6">NA</td>
<td headers="t4h7">NA</td>
</tr>

<tr>
<td headers="t4h1"><span class="bold">Children—</span> (1-10 years)</td>
<td headers="t4h2">5 § §</td>
<td headers="t4h3">0.5</td>
<td headers="t4h4">10</td>
<td headers="t4h5">0.5</td>
<td headers="t4h6">NA</td>
<td headers="t4h7">NA</td>
</tr>

<tr>
<td headers="t4h1"><span class="bold">Adolescents</span> 11-17 years</td>
<td headers="t4h2">NA</td>
<td headers="t4h3">NA</td>
<td headers="t4h4">NA</td>
<td headers="t4h5">NA</td>
<td headers="t4h6">NA</td>
<td headers="t4h7">NA</td>
</tr>

<tr>
<td headers="t4h1"><span class="bold">Adults—</span> 18 years or older</td>
<td headers="t4h2">NA</td>
<td headers="t4h3">NA</td>
<td headers="t4h4">NA</td>
<td headers="t4h5">NA</td>
<td headers="t4h6">20</td>
<td headers="t4h7">1.0</td>
</tr>
</table>

<p class="bold smallFontSize">* Hepatitis B vaccines are administered by intramuscular injection and may be given at the same time as other vaccines. Single-antigen vaccines may be administered with HBIG, but in a separate injection site.<br />
† For persons ≥18 years of age at increased risk of both hepatitis B virus and hepatitis A virus infection<br />
§ Recombinant HBsAg protein concentration<br />
¶ Comvax also contains combined hepatitis B-Haemophilus influenzae type B conjugate vaccine. This vaccine cannot be administered at birth, before age 6 weeks, or after age 71 months.<br />
** Pediarix also contains combined hepatitis B-25 Lf diphtheria toxoid, 10 Lf tetanus toxoid, 25 μg inactivated pertussis toxin, 25 μg filamentous hemagglutinin, 8 μg pertactin, 40 D-Wantigen Units (DU) Type 1 poliovirus, 8 DU Type 2 poliovirus, and 32 DU Type 3 poliovirus (cannot be administered at ages &#62;7 years.<br />
† †Twinrix also contains 720 ELISA Units (EL.U) inactivated hepatitis A virus.<br />
§§ Maximum age at administration is 71 months.<br />
&#160;</p>

<hr />
<p>An infant born to a HBsAg-positive woman who has not received HBIG and the first dose of hepatitis B vaccine by 12 hours of age or who has not received the third dose of hepatitis B vaccine by the age of 6 months is not adequately vaccinated.<a href="chpt04-hepb.html#f10">[10]</a> Infants born to HBsAg-positive mothers should be tested for HBsAg and antibody to HBsAg after completion of three or more doses in a licensed hepatitis B vaccination series, at age 9-18 months (generally at the next well-child visit). The testing should be done 1-2 months after the most recent hepatitis B vaccine dose to avoid a positive HBsAg result due to vaccine. Serologic testing can determine whether these infants are infected or have developed a protective antibody response after vaccination. Infants who do not respond to the primary vaccination series should be given three additional doses of hepatitis B vaccine on a 0, 1-2, 4-6-month schedule and re-tested 1-2 months after the final dose of vaccine.</p>

<p>The vaccination schedule for infants born to HBsAg-negative women includes three doses of vaccine in the first 18 months of life. The first dose should be given at birth with a minimum interval between doses 1 and 2 of 4 weeks; and a minimum interval of 8 weeks between doses 2 and 3.<a href="chpt04-hepb.html#f10">[10]</a> Dose 3 of hepatitis B vaccine should not be given before 24 weeks of age (164 days). Any infant born to an HBsAg-negative woman who has not received the third dose of hepatitis B vaccine by the age of 19 months is considered not up-to-date (Table 5).</p>

<h4><a id="t5" name="t5"> </a>Table 5.Hepatitis B vaccine schedules for newborn infants, by maternal hepatitis B surface antigen (HBsAg) status*</h4>

<table class="opt-in table table-bordered"><thead class="primary-bg-color">
<tr>
<th id="t5h1">Maternal HBsAg Status</th>
<th id="t5h2">Single-Antigen Vaccine</th>
<th id="t5h3">Single-Antigen + Combination Vaccine</th>
</tr>

</thead>
<tr>
<td headers="t5h1">Positive</td>
<td headers="t5h2"><span class="bold">Dose:</span> 1†<br />
<span class="bold">Age:</span> Birth (12 hours or younger)</td>
<td headers="t5h3"><span class="bold">Dose:</span> 1†<br />
<span class="bold">Age:</span> Birth (12 hours or younger)</td>
</tr>

<tr>
<td headers="t5h1">Positive</td>
<td headers="t5h2"><span class="bold">Dose:</span> HBIG§<br />
<span class="bold">Age:</span> Birth (12 hours or younger)</td>
<td headers="t5h3"><span class="bold">Dose:</span> HBIG§<br />
<span class="bold">Age:</span> Birth (12 hours or younger)</td>
</tr>

<tr>
<td headers="t5h1">Positive</td>
<td headers="t5h2"><span class="bold">Dose:</span> 2<br />
<span class="bold">Age:</span> 1-2 months</td>
<td headers="t5h3"><span class="bold">Dose:</span> 2<br />
<span class="bold">Age:</span> 2 months</td>
</tr>

<tr>
<td headers="t5h1">Positive</td>
<td headers="t5h2"><span class="bold">Dose:</span> 3¶<br />
<span class="bold">Age:</span> 6 months</td>
<td headers="t5h3"><span class="bold">Dose:</span> 3<br />
<span class="bold">Age:</span> 4 months</td>
</tr>

<tr>
<td headers="t5h1">Positive</td>
<td headers="t5h2">&#160;</td>
<td headers="t5h3"><span class="bold">Dose:</span> 4¶<br />
<span class="bold">Age:</span> 6 months (Pediarix) or<br />
12-15 months (Comvax)</td>
</tr>

<tr>
<td headers="t5h1">Unknown**</td>
<td headers="t5h2"><span class="bold">Dose:</span> 1†<br />
<span class="bold">Age:</span> Birth (less than or equal 12 hours)</td>
<td headers="t5h3"><span class="bold">Dose:</span> 1†<br />
<span class="bold">Age:</span> Birth (less than or equal 12 hours)</td>
</tr>

<tr>
<td headers="t5h1">Unknown**</td>
<td headers="t5h2"><span class="bold">Dose:</span> 2<br />
<span class="bold">Age:</span> 1-2 months</td>
<td headers="t5h3"><span class="bold">Dose:</span> 2<br />
<span class="bold">Age:</span> 2 months</td>
</tr>

<tr>
<td headers="t5h1">Unknown**</td>
<td headers="t5h2"><span class="bold">Dose:</span> 3¶<br />
<span class="bold">Age:</span> 1-2 months</td>
<td headers="t5h3"><span class="bold">Dose:</span> 3<br />
<span class="bold">Age:</span> 4 months</td>
</tr>

<tr>
<td headers="t5h1">Unknown</td>
<td headers="t5h2">&#160;</td>
<td headers="t5h3"><span class="bold">Dose:</span> 4¶<br />
<span class="bold">Age:</span> 6 months (Pediarix) or<br />
12-15 months (Comvax)</td>
</tr>

<tr>
<td headers="t5h1">Negative</td>
<td headers="t5h2"><span class="bold">Dose:</span> 1†,††<br />
<span class="bold">Age:</span> Birth (before discharge)</td>
<td headers="t5h3"><span class="bold">Dose:</span> 1†,††<br />
<span class="bold">Age:</span>Birth (before discharge)</td>
</tr>

<tr>
<td headers="t5h1">Negative</td>
<td headers="t5h2"><span class="bold">Dose:</span> 2<br />
<span class="bold">Age:</span> 1-2 months</td>
<td headers="t5h3"><span class="bold">Dose:</span> 2<br />
<span class="bold">Age:</span> 2 months</td>
</tr>

<tr>
<td headers="t5h1">Negative</td>
<td headers="t5h2"><span class="bold">Dose:</span> 3¶<br />
<span class="bold">Age:</span> 6 months</td>
<td headers="t5h3"><span class="bold">Dose:</span> 3<br />
<span class="bold">Age:</span> 4 months</td>
</tr>

<tr>
<td headers="t5h1">Negative</td>
<td headers="t5h2">&#160;</td>
<td headers="t5h3"><span class="bold">Dose:</span> 4¶<br />
<span class="bold">Age:</span>6 months (Pediarix) or<br />
12-15 months (Comvax)</td>
</tr>
</table>

<p class="bold smallFontSize">* Centers for Disease Control and Prevention. A comprehensive strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP); Part 1: Immunization of Infants, Children and Adolescents. MMWR 2005;54(No. RR-16) p.9.<br />
† Recombivax HB or Engerix-B should be used for the birth dose. Comvax and Pediarix cannot be administered at birth or before age 6 weeks.<br />
§ Hepatitis B immune globulin (0.5 mL) administered intramuscularly in a separate site from vaccine.<br />
¶ The final dose in the vaccine series should not be administered before age 24 weeks (164 days).<br />
** Mothers should have blood drawn and tested for HBsAg as soon as possible after admission for delivery;<br />
if the mother is found to be HBsAg positive, the infant should receive HBIG as soon as possible but no later than 7 days of age.<br />
††On a case-by-case basis and only in rare circumstances, the first dose may be delayed until after hospital discharge for an infant who weighs ≥2,000 g and whose mother is HBsAg negative. When such a decision is made, a physician’s order to withhold the birth dose and a copy of the original laboratory report indicating that the mother was HBsAg negative during this pregnancy should be placed in the infant’s medical record.</p>

<br />
<hr />
<p>Vaccination of pre-term infants should be delayed until they are 1 month old or at time of discharged from hospital, except for infants born to HBsAg-positive women and infants born to women with unknown HBsAg status. Infants born to HBsAg-positive women or women with unknown HBsAg status should be immunized with HBIG within 12 hours of birth regardless of birth weight.</p>

<h3>Children and adolescents</h3>

<p>Vaccination is routinely given as three-dose series at 0, 1, and 6 months. Acceptable alternative schedules include 0, 1, 2, 12 months and 0, 2, 4 months.</p>

<h3>Adolescents 11-15 years of age</h3>

<p>An alternative two-dose vaccination schedule has been developed for use in adolescents. The adult dose of Recombivax HB is administered to the adolescent, with the second dose given 4-6 months or 0, 1, 2, and 12 months after the first dose.</p>

<h3>Adults (20 years of age or older)</h3>

<p>Routinely given as three-dose series at 0, 1, and 6 months. Acceptable alternative schedules are 0, 1, 4 months and 0, 2, 4 months, and 0, 1, 2, and 12 months.</p>

<h3>Dialysis patients and other immunocompromised persons</h3>

<p>Either given as a three-dose series (0, 1, 6 months) or four-dose series (0, 1, 2, and 6 months), depending on formulation. Larger vaccine doses may be required to induce protective antibody levels in other immunocompromised persons (e.g., those taking immunosuppressive drugs, HIV infected), although few data are available concerning response to higher doses of vaccine in these patients and no data exist for children.</p>

<h3>Combined hepatitis A and B vaccine</h3>

<p>Primary vaccination of persons aged 18 years and older consists of three doses, administered on a 0, 1, and 6-month schedule.</p>

<p><span class="toTop"><span class="icon-angle-up"><!-- --></span><a href="chpt04-hepb.html#">Top of Page</a></span></p>

<h2><a class="onThisPageAnchor" id="enhancing-surveillance" name="enhancing-surveillance" title="Enhancing Surveillance"> </a>Enhancing Surveillance</h2>

<p>Establishing surveillance for acute hepatitis is difficult for several reasons. Five different viruses (A-E) cause viral hepatitis, and the clinical manifestations of the different types of acute hepatitis are similar. Infection with HBV, HCV and HDV can result in both acute and chronic infection. Therefore, serologic testing is necessary to establish an etiologic diagnosis for persons with symptoms of acute hepatitis and to evaluate case reports of persons who are reported with viral hepatitis. However, a lack of understanding about the epidemiology of these diseases and underutilization of serologic testing could result in significant misclassification in reporting of acute viral hepatitis.</p>

<h3>Provider education</h3>

<p>Providers should be educated about the importance of performing appropriate serologic tests to determine the etiology of viral hepatitis and reporting all cases of acute hepatitis B, chronic hepatitis B, and perinatal HBV. Case investigations of infected persons provide the best opportunity for postexposure prophylaxis of contacts and for reducing transmission.</p>

<h3>Case investigation</h3>

<p>Case investigation is essential for determining contacts who are eligible for prophylaxis and for collection of risk factor data. Analysis of risk factor data can identify populations where targeted interventions may be needed.</p>

<h3>Laboratory reporting</h3>

<p>Laboratories should be encouraged to report all persons with serologic markers of acute or chronic hepatitis to the state or local health department. All IgM anti-HBc, and HBsAg positive results should be reported. To facilitate reporting, these laboratory results could be included in the state’s list of laboratory-reportable conditions.</p>

<h3>Monitoring surveillance indicators</h3>

<p>Regular monitoring of surveillance indicators, including date of report, timeliness, and completeness of reporting, may identify specific areas of the surveillance and reporting system that need improvement. Important program indicators that can be monitored through the surveillance, reporting and case investigation system include the following:</p>

<ul>
<li>Characteristics of cases of acute hepatitis B that occur in children and adolescents younger than 20 years of age and missed opportunities for vaccination.</li>

<li>Characteristics of cases of acute hepatitis in which death has occurred.</li>

<li>Characteristics of cases of acute hepatitis B in persons reporting a history of vaccination.</li>

<li>Characteristics of cases of acute hepatitis B in persons over 70 years of age.</li>

<li>Characteristics of cases of acute hepatitis B associated with healthcare transmission.</li>

<li>Characteristics of cases of perinatal hepatitis B.</li>
</ul>

<h3>Registries/databases for HBsAg-positive persons</h3>

<p>Reporting of HBsAg-positive test results and establishment of databases/registries for HBsAg-positive persons is encouraged. When any type of database is established, the confidentiality of individual identifying information needs to be ensured according to applicable laws and regulations. Computerized databases of persons with HBsAg-positive results can be used to:</p>

<ul>
<li>Distinguish newly reported cases of infection from previously identified cases and facilitate reporting of chronic hepatitis B;</li>

<li>Facilitate case investigation and follow-up of persons with chronic HBV infection;</li>

<li>Provide local, state, and national estimates of the proportion of persons with chronic HBV infection who have been identified.</li>
</ul>

<h3>Hospital-based reporting</h3>

<p>Hospitals and infection control practitioners should be encouraged to report all persons with acute viral hepatitis (ICD-10 code B16), and all births to HBsAg-positive women.</p>

<p><span class="toTop"><span class="icon-angle-up"><!-- --></span><a href="chpt04-hepb.html#">Top of Page</a></span></p>

<h2><a class="onThisPageAnchor" id="case-investigation" name="case-investigation" title="Case Investigation"> </a>Case Investigation</h2>

<p>Guidelines for investigating a suspected case of acute viral hepatitis include</p>

<ol>
<li>determining a discrete onset of illness,</li>

<li>confirming evidence of acute liver disease (jaundice or elevated aminotransferase levels), and</li>

<li>obtaining serologic laboratory results.</li>
</ol>

<p>The minimum recommended elements for investigating cases of chronic HBV infection and perinatal HBV infection include obtaining the serologic laboratory results needed to establish the case. Further investigation to determine the clinical characteristics of these cases may also be considered although it is not required to confirm the case.</p>

<h3>Information to collect for acute hepatitis B</h3>

<p>The following information is epidemiologically important to collect in a case investigation for acute hepatitis B.<a href="chpt04-hepb.html#f18">[18, 19]</a>Additional information may also be collected at the direction of the state health department.</p>

<ul>
<li>Demographic information

<ul>
<li>Clinical details</li>

<li>Date of illness onset</li>
</ul>
</li>

<li>Symptoms, including jaundice</li>

<li>Laboratory results</li>

<li>Vaccination status</li>

<li>Risk behaviors/exposures</li>

<li>Contact investigation and prophylaxis</li>
</ul>

<h3>Information to collect for chronic HBV infection</h3>

<p>The following information is epidemiologically important to collect in a case investigation for chronic hepatitis B virus infection. Additional information may also be collected at the direction of the state health department.<a href="chpt04-hepb.html#f19">[19]</a></p>

<ul>
<li>Demographic information</li>

<li>Laboratory results</li>

<li>Risk behaviors/exposures</li>

<li>Pregnancy status. All HBsAg-positive pregnant women should be reported to the perinatal hepatitis B program manager so that they can be tracked and their infants can receive appropriate case management</li>
</ul>

<p>The recommended elements of case investigation and follow-up of persons with chronic hepatitis B virus infection are detailed elsewhere.<a href="chpt04-hepb.html#f20">[20]</a> The following should be included:</p>

<ul>
<li>Contact investigation and prophylaxis: Provision of hepatitis B vaccination for sexual, household, and other (needle-sharing) contacts of persons with hepatitis B, and counseling to prevent transmission to others</li>

<li>Counseling and referral for medical management, including

<ul>
<li>assessing for biochemical evidence of chronic liver disease, and</li>

<li>evaluating eligibility for antiviral treatment.<a href="chpt04-hepb.html#f18">[18]</a></li>
</ul>
</li>
</ul>

<h3>Information to collect for perinatal HBV infection</h3>

<p>The following information is epidemiologically important to collect in a case investigation for perinatal HBV infection:</p>

<ul>
<li>Demographic information about the child and mother</li>

<li>Laboratory results</li>

<li>Immunization history of the child, including date and doses of HBIG and hepatitis B vaccine</li>
</ul>

<p>Case investigation and follow-up of infants with hepatitis B virus infection should include the following:</p>

<ul>
<li>Referral for medical management, including

<ul>
<li>Assessing for biochemical evidence of chronic liver disease, and</li>

<li>Evaluating eligibility for antiviral treatment</li>
</ul>
</li>

<li>Identification of other susceptible infants and children in the household who require vaccination</li>
</ul>

<hr />
<h3>References</h3>

<ol>
<li><a id="f1" name="f1"> </a>McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. <em>J Infect Dis</em> 1985;151:599-603.</li>

<li><a id="f2" name="f2"> </a>CDC. Division of Viral Hepatitis. <a href="https://www.cdc.gov/hepatitis/PDFs/disease_burden.pdf">Disease Burden from Viral Hepatitis A, B, and C in the United States [5 pages]</a>. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. (Accessed February 10, 2011).</li>

<li><a id="f3" name="f3"> </a>Wasley A, Kruszon-Moran D, Kuhnert W, et al. The prevalence of hepatitis B virus infection in the Unites States in the era of vaccination. <em>J Infect Dis</em> 2010; 202(2):192-201.</li>

<li><a id="f4" name="f4"> </a>Edmunds WJ, Medley GF, Nokes DJ, Hall AJ, Whittle HC. The influence of age on the development of the hepatitis B carrier state. <em>Lancet</em> 1993; 337:197-201.</li>

<li><a id="f5" name="f5"> </a>Franks AL, Berg CJ, Kane MA, Browne BB, Sikes RK, Elsea WR, et al. Hepatitis B infection among children born in the United States to southeast Asian refugees.<br />
<em>N Engl J Med</em> 1989;321:1301-5.</li>

<li><a id="f6" name="f6"> </a>Hurie MB, Mast EE, Davis JP. Horizontal transmission of hepatitis B virus infection to United States-born children of Hmong refugees. <em>Pediatrics</em> 1992;89:269-73.</li>

<li><a id="f7" name="f7"> </a>Mahoney F, Lawrence M, Scott C, Le Q, Lambert S, Farley TA. Continuing risk for hepatitis B virus transmission among infants in Louisiana. <em>Pediatrics</em> 1995;96:1113-6.</li>

<li><a id="f8" name="f8"> </a>Pon EW, Ren H, Margolis H, Zhao Z, Schatz GC, Diwan A. Hepatitis B virus infection in Honolulu students. <em>Pediatrics</em> 1993;92:574-8.</li>

<li><a id="f9" name="f9"> </a>CDC.. Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee <em>MMWR</em> 1991;40:(No. RR-13):1-25.</li>

<li><a id="f10" name="f10"> </a>CDC. A comprehensive strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP); Part 1: Immunization of infants, children and adolescents. <em>MMWR</em> 2005;54(No. RR-16).</li>

<li><a id="f11" name="f11"> </a>CDC. Surveillance for acute viral hepatitis - United States, 2007. <em>MMWR</em> 2009; 58 (No. SS-3).</li>

<li><a id="f12" name="f12"> </a>Healthy People 2020. <a href="http://www.healthypeople.gov/2020/topicsobjectives2020/default.aspx">Healthy People 2020 Objectives.</a> (Accessed March 9, 2011)</li>

<li><a id="f13" name="f13"> </a>CDC. Case definitions for infectious conditions under public health surveillance.</li>

<li><a id="f14" name="f14"> </a>Council for State and Territorial Epidemiologists. <a href="http://www.cste.org/dnn/ProgramsandActivities/PublicHealthInformatics/StateReportableConditionsQueryResults/tabid/261/Default.aspx">State Reportable Conditions Assessment (2010)</a>, (Accessed March 10, 2011)</li>

<li><a id="f15" name="f15"> </a>CDC. <a href="https://www.cdc.gov/phin/library/phin_fact_sheets/111759_NEDSS.pdf">National Electronic Disease Surveillance System [2 pages]</a> (Accessed February 7, 2011)</li>

<li><a id="f16" name="f16"> </a>CDC. <a href="../../../ncezid/dpei.1.html">Emerging Infections Programs</a> (Accessed February 7, 2011)</li>

<li><a id="f17" name="f17"> </a>Dienstag JL. Hepatitis B virus infection. <em>N Engl J Med.</em> 2008; 359:1486-1500.</li>

<li><a id="f18" name="f18"> </a>CDC. Division of Viral Hepatitis. Guidelines for viral hepatitis surveillance and case management. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, July 2005.</li>

<li><a id="f19" name="f19"> </a>Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, Kern ER, McHugh JA, Petersen GM, Rein MF, Strader DB, Trotter HT. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis B. <em>Ann Intern Med.</em> 2009;150(2):104-10.</li>

<li><a id="f20" name="f20"> </a>CDC. A comprehensive strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP); Part 2: Immunization of adults. <em>MMWR</em> 2006; 55(No. RR-16).</li>
</ol>

<span class="toTop"><span class="icon-angle-up"><!-- --></span>&#160;<a href="chpt04-hepb.html#">Top of Page</a></span>
<div class="module-typeH">
<h3>Related Pages</h3>

<ul class="list-block">
<li><a href="https://www.cdc.gov/vaccines/ed/surv/index.html">Webcast related to this manual</a></li>

<li><a href="https://www.cdc.gov/hepatitis/ChooseB.htm">CDC Hepatitis B web site</a></li>

<li><a href="https://www.cdc.gov/hepatitis/ChooseB.htm">Surveillance Guidelines and Forms</a></li>

<li><a href="https://www.cdc.gov/hepatitis/HAV/StatisticsHAV.htm#section4">Hepatitis B disease burden</a></li>

<li><a href="../../vpd-vac/hepb/default.htm#clinical">Hepatitis B vaccination</a></li>

<li><a href="http://hepbtaskforce.org/">National Hepatitis B Initiative for Asian Americans/Native Hawaiian and Other Pacific Islanders</a>&#62;</li>
</ul>
</div>
             					            					            						</div>
            					            					            						</div>
            													        						                                                                                        						                                                                								<!-- Related Nav Area -->
								<div class="nav-related hidden-three hidden-four">
									


<div class="module-typeG emailupdates">
<span class="sprite-24-govd-icon"><!-- span --></span> <h4>Get Email Updates</h4>
<p>To receive email updates about this page, enter your email address:</p>
<form action="https://public.govdelivery.com/accounts/USCDC/subscribers/qualify" name="govdelivery">
<fieldset>
<input name="topic_id" type="hidden" value="USCDC_11_40">
<label>
<span class="hidden">Enter Email Address</span>
<input class="email" name="email" type="text" value="">
</label>
<a class="explain" href="../../../emailupdates/index.html">What's this?</a>
<a class="button" href="chpt04-hepb.html#;">Submit</a>

<noscript>&lt;a class="explain" href="https://www.cdc.gov/emailupdates/"&gt;What's this?&lt;/a&gt; &lt;label&gt;&lt;span class="hidden"&gt;Submit Button&lt;/span&gt; &lt;input class="button submit" name="commit" type="submit" value="Submit" /&gt;&lt;/label&gt;</noscript>
</fieldset>
</form>
</div>

									



	    <div class="module-typeH">
		<h3>Related Links</h3>
		<div>
																	<ul class="list-block">																														<li>					
<a href="../../index.html">Vaccines &amp; Immunizations</a>					</li>										</ul>														</div>
	</div>
	  



								</div>
    							<!-- Persistent Content Area -->
    							<div id="content-secondary">
                                    



            						




    							</div><!-- /end #content-secondary -->
    						</div><!-- /end #contentArea -->
    					</div><!-- /end body -->	
					</div>
					<div class="row">
						<div class="span24 visible-one">
														<div class="pageoptionsContainer formatOptions formatOptionsOff"><span id="po-format-label-bottom" class="select-label">Format:</span><div id="po-format-bottom" class="format pageoptions pull-right"><div class="select-box"><a href="chpt04-hepb.html#">Select one</a><span class="icon-angle-down pull-right poarrow"></span></div><ul class="drop-down" aria-labelledby="po-format-label-bottom"><li>
        			    	<a class="noDecoration" href="https://www.cdc.gov/vaccines/pubs/surv-manual/chpt04-hepb.pdf" target="_blank"><span class="sprite-16-pdf"></span> PDF [462 KB]</a>
      </li></ul></div></div>													</div>
					</div>
					<div class="row">
						<div class="span24">
                            <div id="plugin-legend" class="pluginOff">
	<h5>File Formats Help:</h5><span><a href="../../../Other/plugins/index.html">How do I view different file formats (PDF, DOC, PPT, MPEG) on this site?</a></span>
	<ul>
		<li class="plugin-pdf"><a href="../../../Other/plugins/index.html#pdf"><span class="sprite-16-pdf">Adobe PDF file</span></a></li>
		<li class="plugin-ppt"><a href="../../../Other/plugins/index.html#ppt"><span class="sprite-16-ppt">Microsoft PowerPoint file</span></a></li>
		<li class="plugin-word"><a href="../../../Other/plugins/index.html#doc"><span class="sprite-16-word">Microsoft Word file</span></a></li>
		<li class="plugin-excel"><a href="../../../Other/plugins/index.html#xls"><span class="sprite-16-excel">Microsoft Excel file</span></a></li>
		<li class="plugin-wmv"><a href="../../../Other/plugins/index.html#wmv"><span class="sprite-16-wmv">Audio/Video file</span></a></li>
		<li class="plugin-qt"><a href="../../../Other/plugins/index.html#qt"><span class="sprite-16-qt">Apple Quicktime file</span></a></li>
		<li class="plugin-real"><a href="../../../Other/plugins/index.html#ram"><span class="sprite-16-rp">RealPlayer file</span></a></li>
		<li class="plugin-text"><a href="../../../Other/plugins/index.html#text"><span class="sprite-16-txt">Text file</span></a></li>
		<li class="plugin-zip"><a href="../../../Other/plugins/index.html#zip"><span class="sprite-16-zip">Zip Archive file</span></a></li>
		<li class="plugin-sas"><a href="../../../Other/plugins/index.html#sas"><span class="sprite-16-sas">SAS file</span></a></li>
		<li class="plugin-epub"><a href="../../../Other/plugins/index.html#epub"><span class="sprite-16-ebook">ePub file</span></a></li>
		<li class="plugin-ris"><a href="../../../Other/plugins/index.html#ris"><span class="sprite-16-ris">RIS file</span></a></li>
	</ul>
</div>
						</div>
					</div>
					<!-- date stamp -->
					<div id="datestamp" class="row" itemscope="itemscope" itemtype="http://schema.org/WebPage">
						<div class="span24">
    						<ul> 
            					            						<li class="last-reviewed">Page last reviewed: <span itemprop="lastReviewed">April 1, 2014</span></li>
            													            					            						<li class="last-updated">Page last updated: <span itemprop="dateModified">April 1, 2014</span></li>
            					        							<li class="content-source">Content source:
    									



<ul>
<li itemprop="sourceOrganization" itemscope="itemscope" itemtype="http://schema.org/Organization"><a href="../../../ncird/index.html">National Center for Immunization and Respiratory Diseases</a></li>
</ul>


        							</li>
									



    						</ul>
						</div>
					</div>					
				</div><!-- /end #content -->
			</div><!-- /.container for content -->					
			<!-- footer -->
				<footer id="footer" class="cdcSlimFooter">
	
 <!-- include eng footerSubSocialMedia.html -->
<div class="socialMedia">
	<div class="container">
		<nav class="followcdc">
			<ul>
				<li><a href="../../../Other/emailupdates.1.html"><span class="sprite-24-govd"></span><span class="tp-sr-only">Email</span></a></li>
				<li><a href="https://www.facebook.com/CDC" target="_blank"><span class="sprite-24-facebook"></span><span class="tp-sr-only">Recommend</span></a></li>
				<li><a href="https://twitter.com/CDCgov" target="_blank"><span class="sprite-24-twitter"></span><span class="tp-sr-only">Tweet</span></a></li>
				<li><a href="https://www.youtube.com/user/CDCstreamingHealth" target="_blank"><span class="sprite-24-youtube"></span><span class="tp-sr-only">YouTube</span></a></li>
				<li><a href="https://www.instagram.com/CDCgov/" target="_blank"><span class="sprite-24-instagram"></span><span class="tp-sr-only">Instagram</span></a></li>
			</ul>
		</nav>
		<nav class="cdcmedia">
			<ul>
				<li><a href="https://www2c.cdc.gov/podcasts"><span class="sprite-24-listen"></span><span class="tp-sr-only">Listen</span></a></li>
				<li><a href="../../../cdctv.1.html"><span class="sprite-24-watch"></span><span class="tp-sr-only">Watch</span></a></li>
				<li><a href="https://www2c.cdc.gov/podcasts/rss.asp"><span class="sprite-24-rss"></span><span class="tp-sr-only">RSS</span></a></li>
			</ul>
		</nav>
	</div>
</div>
 <!-- /include eng footerSubSocialMedia.html -->

	<div class="container">
		<div class="cdcLinks">
			<div class="container">
				<ul>
					
<!-- include eng footerSubCdcLinks.html-->
<li>
	<nav>
		<h6 class="hidden-four hidden-three">ABOUT <span class="icon-plus visible-one pull-right"></span></h6>
		<ul class="hidden-one">
			<li><a href="../../../about/default.htm">About CDC</a></li>
			<li><a href="https://jobs.cdc.gov">Jobs</a></li>
			<li><a href="../../../funding.1.html">Funding</a></li>
		</ul>
	</nav>
</li>
<li>
	<nav>
		<h6 class="hidden-four hidden-three">LEGAL <span class="icon-plus visible-one pull-right"></span></h6>
		<ul class="hidden-one">
			<li><a href="../../../Other/policies.html">Policies</a></li>
			<li><a href="../../../Other/privacy.html">Privacy</a></li>
			<li><a href="../../../od/foia.1.html">FOIA</a></li>
			<li><a href="../../../eeo/nofearact/index.htm">No Fear Act</a></li>
			<li><a href="https://oig.hhs.gov" class="no-link">OIG</a></li>
		</ul>
	</nav>
</li>
<!--/ include eng footerSubCdcLinks.html-->

				</ul>
			</div>
		</div>
		<div class="cdcContact">
			<div class="container">
				<ul>
					<li class="local-contact">
						
 <!-- include eng footerSubGlobalContact1.html -->
<section>
	<address class="address" itemscope="itemscope" itemtype="https://schema.org/Organization">
		<span class="value" itemprop="address" itemscope="itemscope" itemtype="https://schema.org/PostalAddress">
			<span itemprop="streetAddress">1600 Clifton Road</span>
			<span itemprop="addressLocality">Atlanta</span>,
			<span itemprop="addressRegion">GA</span>
			<span itemprop="postalCode">30329-4027</span>
			<span itemprop="addressCountry">USA</span>
		</span><br />
		<span class="value" itemprop="telephone">800-CDC-INFO (800-232-4636)</span>,
		<span class="value" itemprop="telephone">TTY: 888-232-6348</span><br />
		<span class="value" itemprop="contactPoint" itemscope="itemscope" itemtype="https://schema.org/ContactPoint">
			<span itemprop="url"><a href="https://wwwn.cdc.gov/dcs/RequestForm.aspx" class=" default no-link">Email CDC-INFO</a></span>
		</span>
	</address>
</section>
 <!-- /include eng footerSubGlobalContact1.html -->

					</li>
					<li class="contact">
						
 <!-- include eng footerSubGlobalContact2.html -->
<section>
	<address class="address" itemscope="itemscope" itemtype="https://schema.org/Organization">
		<span class="value" itemprop="contactPoint" itemscope="itemscope" itemtype="https://schema.org/ContactPoint">
			<span itemprop="url"><a href="https://www.hhs.gov" class="no-link">U.S. Department of Health & Human Services</a></span>
		</span><br />
        <span class="value" itemprop="contactPoint" itemscope="itemscope" itemtype="https://schema.org/ContactPoint">
        	<span itemprop="url"><a href="https://www.hhs.gov/open" class="no-link">HHS/Open</a></span>
        </span><br />
        <span class="value" itemprop="contactPoint" itemscope="itemscope" itemtype="https://schema.org/ContactPoint">
			<span itemprop="url"><a href="https://www.usa.gov/" class="no-link">USA.gov</a></span>
		</span>
	</address>
</section>
 <!-- /include eng footerSubGlobalContact2.html -->

					</li>
				</ul>
			</div>
		</div>
	</div>
</footer>			<!-- /#footer -->
			<div id="totop" class="off visible-one">Top</div>
        </div>
		<script>page_timing.libs_start = Date.now();</script><script src="../../../TemplatePackage/3.0/js/libs.min.js@3.2.1.7"></script><script>page_timing.libs_end = Date.now();page_timing.core_start = Date.now();</script><script src="../../../TemplatePackage/3.0/js/core.min.js@3.2.1.7"></script><script>page_timing.core_end = Date.now();</script><!-- Start Site Settings Overrides -->
<script>
CDC.Constants.set("flexSliderVideoDomains", ['youtube.com','ytimg.com','vimeocdn.com'], 'es');
</script>
<!-- End Site Settings Overrides --><script>page_timing.app_start = Date.now();</script><script src="../../../TemplatePackage/3.0/js/app.min.js@3.2.1.7"></script><script>page_timing.app_end = Date.now();</script>		
		        <script src="../../../TemplatePackage/3.0/js/libs/lazyloadxt/jquery.lazyloadxt.min.js"></script>
        <script src="../../../TemplatePackage/3.0/js/libs/lazyloadxt/jquery.lazyloadxt.extra.min.js"></script>

        			<!-- Begin Survey scripts -->
<script src="../../../JScript/foresee/foresee-trigger.js"></script>
<script src="../../../JScript/foresee-variables.js"></script>
<!-- End Survey scripts -->
			
            <script>if (typeof page_timing !== 'undefined') { page_timing.metrics_start = Date.now(); }</script>
<!-- xxxxxxxxxxxxxxxxxx METRICS code begins here xxxxxxxxxxxxxxxxxxxxxxxxxxx-->
<div id="metrics">

<!-- Begin Google DAP inclusion -->
<script type="text/javascript" id="_fed_an_ua_tag" src="../../../JScript/metrics/google/Universal-Federated-Analytics-Min.js@agency=HHS&amp;subagency=CDC"></script>
<!-- End Google DAP inclusion -->

<!-- Begin Template Package Custom Interactions -->
<script type="text/javascript" src="../../../JScript/metrics/rd_custom_interactions.js"></script>
<!-- End Template Package Custom Interactions -->

<!-- SiteCatalyst code version: H.21. -->
<script src="../../../JScript/metrics/topic_levels.js"></script>
<script src="../../../JScript/metrics/s_code_v21_cdcgov.js"></script>
<script>

	enquire.register(CDC.Global.selectors.vp1, function() {
		s.prop49 = 1;
	});
	enquire.register(CDC.Global.selectors.vp2, function() {
		s.prop49 = 2;
	});
	enquire.register(CDC.Global.selectors.vp3, function() {
		s.prop49 = 3;
	});
	enquire.register(CDC.Global.selectors.vp4, function() {
		s.prop49 = 4;
	});

            
            


s.pageName=document.title
s.channel="Vaccines" 
siteCatalyst.setLevel1("ncird"); <!--formerly NCIRD before 8/15/2012--><!-- OLD LEVEL 1 = "NCIRD" BEFORE 3/5/2013 -->
siteCatalyst.setLevel2("Vaccines"); <!-- OLD LEVEL 2 = "Surveillance" BEFORE 3/5/2013 -->
siteCatalyst.setLevel3("php"); <!-- NEW LEVEL 3 AS OF 3/5/2013 -->
siteCatalyst.setLevel4("surv-manual"); <!-- NEW LEVEL 4 AS OF 3/5/2013 -->


            
                        
            s.prop2=window.location.href;
s.prop26=document.title;
s.prop30=document.title;
s.prop31=window.location.href;
s.prop46=window.location.href;
s.server=window.location.hostname;

// Update the level variables here.
updateVariables(s);

/************* DO NOT ALTER ANYTHING BELOW THIS LINE ! **************/
var s_code=s.t();



if(s_code) {
	document.write(s_code);
}



if (document.location.protocol) {


	var cookieManagment = {
		getUuid : function (strPrefix) {
			strPrefix = strPrefix || "";
			var d = new Date();
			var seconds = Math.round(d.getTime() / 1000);
			return strPrefix + Math.floor((1 + Math.random()) * 0x10000).toString(16).substring(1) + "-" + seconds.toString();
		},
		setCookie : function (cname, cvalue, exdays, domain) {
			domain = domain || ".cdc.gov";
			var d = new Date();
			d.setTime(d.getTime() + (exdays*24*60*60*1000));
			var expires = "expires="+ d.toUTCString();
			document.cookie = cname + "=" + cvalue + ";" + expires + ";domain=" + domain + ";path=/";
		},
		getCookie : function (cname) {
			var name = cname + "=";
			var ca = document.cookie.split(';');
			var i = ca.length;
			while (i --) {
				var c = ca[i];
				while (c.charAt(0)==' ') {
					c = c.substring(1);
				}
				if (c.indexOf(name) == 0) {
					return c.substring(name.length,c.length);
				}
			}
			return "";
		},
		init : function () {



			var currCookieVal = cookieManagment.getCookie('cdc_s_vi');

			if (!currCookieVal.length || currCookieVal.indexOf('[CS]v1') != -1) {
				var newCookieVal = cookieManagment.getUuid('[CS]v2') + "-" + cookieManagment.getUuid('');
				cookieManagment.setCookie("cdc_s_vi", newCookieVal, 7);
				return newCookieVal;
			}
			return currCookieVal;
		}
	};


	var cdcSessionID = cookieManagment.init();

	s3 = s_gi("cdcgovvistorid");

	var sKey, override = {
		fun: "cdcgovvistorid",
		trackingServer: "cdc.112.2o7.net"
	};

	s3.visitorID = cdcSessionID;

	for (sKey in s) {
		if (s.hasOwnProperty(sKey)) {
			if (override.hasOwnProperty(sKey)) {
				s3[sKey] = override[sKey];

			} else {

			}
		}
	}
	updateVariables(s3);


	var s_code_uvid = s3.t();
	if(s_code_uvid) {
		document.write(s_code_uvid);
	}
}




</script>
<script type="text/javascript">
if(navigator.appVersion.indexOf('MSIE')>=0) { document.write(unescape('%3C')+'\!-'+'-'); }
</script>
<noscript><a href="http://www.omniture.com"><img src="https://smtrics.cdc.gov/b/ss/cdcgov/1/H.21--NS/01/H.21--NS/0" height="1" width="1" alt="Web Analytics" /></a></noscript><!--/DO NOT REMOVE/-->
<!-- End SiteCatalyst code version: H.21. -->
<!-- Begin Template Package DigitalGov Search Support -->
<script type="text/javascript" src="../../../JScript/rd_search.js"></script>
<!-- End Template Package DigitalGov Search Support -->
</div>
<!-- xxxxxxxxxxxxxxxxxx METRICS code ends here xxxxxxxxxxxxxxxxxxxxxxxxxxx-->
<script>if (typeof page_timing !== 'undefined') { page_timing.metrics_end = Date.now(); }</script>
				


<script>
<!--//
$(document).ready(function () {
  var cdcLeftNav = new CDC.LeftNav("nav-primary","/migration/ncird_migration/vaccines/pubs/surv-manual/index.html", true, false);
  cdcLeftNav.render();
});
//-->
</script>



    	



						    </body>
	</html>
